Full-Time

Vice President

Data Science

Confirmed live in the last 24 hours

Delfi Diagnostics

Delfi Diagnostics

51-200 employees

Advanced cancer detection using DNA analysis

Compensation Overview

$320k - $370k/yr

Expert

Palo Alto, CA, USA

Hybrid

1-2 designated in-office working days each week for employees who live within 50 miles of Palo Alto, CA or Baltimore, MD offices.

Category
Data Science
Data & Analytics
Required Skills
Python
Data Science
Tensorflow
R
Neural Networks
Pytorch
Machine Learning
AWS
Requirements
  • PhD (or MS and equivalent experience) in Computer Science, Computational Biology / Bioinformatics, Applied Mathematics, Statistics, Physics, or EE
  • 10-15 years’ experience with a wide variety of classical and modern methods used in machine learning and AI (unsupervised, semi-supervised, or supervised learning) as evidenced by strong publication record and/or algorithms released into production
  • 3+ years expertise in developing transformer models, neural networks, and/or representation learning as applied to biological problems
  • 5+ years expertise programming in Python/R including modern ML frameworks (Tensorflow, Pytorch, or Jax), production compute environments (AWS/Nvidia), and versioning principles for reproducible model-building and evaluation
  • 10+ years of experience leading and managing teams exemplifying best practice in recruiting, team-building, employee performance management and career development, goal-setting, and cross-functional collaboration
  • Superb written, verbal communication, and influencing and presentation skills, including the ability to communicate complex concepts succinctly to a variety of audiences
  • Decisive, intellectually curious, proactive, and composed with a balance of high IQ and EQ
Responsibilities
  • Manage and lead a cross-functional team of data scientists, computational biologists, and bioinformatics engineers
  • Oversee the development and delivery of cutting-edge machine learning algorithms to detect cancer from blood samples
  • Collaborate with peers leading assay design & development, laboratory operations, and clinical development to substantively advance DELFI's R&D objectives
  • Partner with IT & cybersecurity team lead to develop a 2-3 year technology roadmap, including in-house tooling for GenAI and ML infrastructure
  • Represent DELFI externally at national and international conferences, and in strategic meetings with academic partners and governmental / regulatory bodies
Desired Qualifications
  • 3+ years of experience working in biotech/pharma/diagnostics
  • Expertise in explainable models, interpretability/white-box models, and federated learning
  • Background or interest in cancer genomics, molecular biology, and the latest genotyping and phenotyping techniques

Delfi Diagnostics focuses on early cancer detection using advanced machine learning and fragmentomics, which involves analyzing fragments of cell-free DNA. Their technology differs from traditional methods by scanning millions of data points to find previously unrecognized cancer-associated fragments, allowing for a more comprehensive detection of cancer. The team includes experts in cancer biology, bioinformatics, and machine learning, led by Dr. Victor Velculescu, a recognized figure in genomics. Delfi's business model is based on providing their cancer detection services to healthcare providers and patients, aiming to improve the efficiency and effectiveness of cancer screening.

Company Size

51-200

Company Stage

Series B

Total Funding

$330.5M

Headquarters

Baltimore, Maryland

Founded

2019

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck's investment accelerates Delfi's cancer detection solutions development and commercialization.
  • Collaboration with City of Hope enhances market reach in underserved communities.
  • Integration into OSF HealthCare's settings boosts technology adoption and validation.

What critics are saying

  • Competition from City of Hope's test may impact Delfi's market share.
  • Reliance on Merck's investment could influence Delfi's strategic decisions.
  • New executive appointments introduce transitional risks in aligning with strategic goals.

What makes Delfi Diagnostics unique

  • Delfi uses fragmentomics to analyze cfDNA for early cancer detection.
  • Their technology identifies unrecognized cancer-associated fragments, unlike traditional mutation-focused methods.
  • Delfi's team includes experts in genomics, bioinformatics, and machine learning.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Parental Leave

Flexible Time Off

Paid Holidays

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

2%
PR Newswire
May 12th, 2025
Delfi Diagnostics Cto Recognized Among 2025 Most Influential Women In Bay Area Business

Dr. Amoolya Singh Honored as Exceptional Business Leader by San Francisco Business TimesBALTIMORE and PALO ALTO, Calif., May 12, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced that its Chief Technology Officer, Dr. Amoolya Singh , has been named to the San Francisco Business Times' 2025 Most Influential Women in Bay Area Business list. Dr. Singh, who was previously named to this list in 2021, joined DELFI in December 2024 and has over two decades of experience working at the intersection of biotechnology and computational science. She boasts an impressive track record of developing breakthrough genomic technologies and products

The Prescott Times
May 12th, 2025
DELFI Diagnostics CTO Recognized among 2025 Most Influential Women in Bay Area Business

DELFI also launched the DELFI-TF Assay and related services to help actively guide critical oncology drug development decisions for pharmaceutical companies.

PR Newswire
Apr 25th, 2025
Delfi Diagnostics To Present Early Detection And Advanced Cancer Monitoring Technology Updates At Aacr Annual Meeting

Fragmentomics pioneer showcases DELFI-TF treatment monitoring solution alongside early detection capabilities at a premier oncology research eventBALTIMORE and PALO ALTO, Calif., April 25, 2025 /PRNewswire/ -- DELFI Diagnostics, Inc ., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring, today announced its team is presenting at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, IL. DELFI is showcasing its groundbreaking DELFI-TF technology for treatment response monitoring alongside its early detection capabilities."Our presentations at AACR highlight how DELFI's fragmentomics platform is transforming both early cancer detection and treatment monitoring," said Victor E. Velculescu, MD, PhD, DELFI Diagnostics Founder and Board Director. "The DELFI technology represents a paradigm shift in how we detect cancer by combining genome-wide fragmentomics of DNA in the blood with AI algorithms for high sensitivity in the screening setting as well as for noninvasively measuring treatment efficacy in advanced cancer patients. "DELFI is presenting multiple podium and poster sessions at AACR, including:Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection presented by Victor E. Velculescu, MD, PhDTuesday, April 29 , 11:06 AM - 11:26 AM CT, Room S100 BC (Grand Ballroom BC) - McCormick Place SouthLeveraging the cfDNA fragmentome to predict immunotherapy response presented by Valsamo Anagnostou, MD, PhDMonday, April 28 , 3:05 PM - 3:20 PM CT, Room S105 - McCormick Place SouthAnalysis of lung cancer clinical characteristics using cell-free DNA fragmentomes presented by Lorenzo Rinaldi, PhDMonday, April 28 , 9:00 AM - 12:00 PM CT, Section 28, Poster 29Cell-free DNA fragmentomes for treatment response monitoring in patients with metastatic colorectal cancer: the DOLPHIN study presented by Denise E

Bizjournals
Oct 30th, 2024
8 things to know: New Under Armour HQ almost complete

Canton-based Delfi Diagnostics has named Robert Guigley as its new chief commercial officer.

PR Newswire
Oct 28th, 2024
DELFI Diagnostics Working with Incendia Therapeutics to Employ Advanced Treatment Monitoring Test in a Phase 1 Clinical Trial

DELFI Diagnostics working with Incendia Therapeutics to employ advanced treatment monitoring test in a Phase 1 clinical trial.